Business
LifeTech Scientific Corporation Announces 2025 Interim Results: Core Business Demonstrated Resilience, Domestic and Overseas Sales Both Increased
LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2025 (the "Reporting Period").
About this update from Lifetech Scientific Corporation
[{"type":"text","content":"HONG KONG, Aug. 30, 2025 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2025 (the "Reporting Period").","length":470,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/先健科技公司)","displaySize":"","headline":null,"caption":"(PRNewsfoto/先健科技公司)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/0e2198d0d2717c2fc73af93eded26f9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bxg4YqFX6gqivJ7Je6XBTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0e2198d0d2717c2fc73af93eded26f9b","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/1744133/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Revenue Growth: The Group achieved revenue of approximately RMB676.7 million during the Reporting Period, representing a year-on-year increase of approximately 3.7%.","length":165,"tagName":"p"},{"type":"text","content":"Stable Profitability: Gross profit was approximately RMB497.8 million. Excluding certain non-recurring items[1], net profit attributable to owners of the Company was approximately RMB238.5 million, representing a year-on-year increase of approximately 2.1%.","length":257,"tagName":"p"},{"type":"text","content":"Strong Cash Position: As at 30 June 2025, the Group's cash and cash equivalents amounted to approximately RMB782.6 million, representing an increase of approximately 17.5% compared with 31 December 2024.","length":212,"tagName":"p"},{"type":"text","content":"Note [1]: Such non-recurring items include (i) the other gains arising from financial assets at fair value through profit or loss ("FVTPL"); and (ii) the share-based payment expenses.","length":193,"tagName":"p"},{"type":"text","content":"Increase in Both Domestic and Overseas Sales","length":44,"tagName":"p"},{"type":"text","content":"In the first half of 2025, the G...